Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)
- 7 June 2019
- journal article
- letter
- Published by Informa UK Limited in Amyloid
- Vol. 26 (3), 173-174
- https://doi.org/10.1080/13506129.2019.1615428
Abstract
(2019). Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14). Amyloid. Ahead of Print.Keywords
This publication has 5 references indexed in Scilit:
- Functional profiling of venetoclax sensitivity can predict clinical response in multiple myelomaLeukemia, 2019
- Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMBlood, 2017
- BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimeticsLeukemia, 2015
- Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based RegimensJournal of Clinical Oncology, 2015
- Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosisBlood, 2001